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Objective: Recent guidelines recommend more aggressive lipid-lowering in secondary prevention proto-
cols. We examined whether this resulted in improved endothelial function.
Methods: We studied saphenous vein specimens of patients undergoing surgical coronary revasculari-
sation in 2007 and compared results with those of patients examined in 2003. Endothelium-dependent
vasodilation was assessed by relaxation to calcium ionophore A23187, and vascular superoxide produc-
tion by lucigenin enhanced chemiluminescence.
Results: Statin dose increased from 26±16mg/d in 2003 to 37±17mg/d in 2007 (P<0.001), and total
(4.0±0.9mmol/L vs 4.8±1.0mmol/L) and LDL-cholesterol levels (2.0±0.7mmol/L vs 3.0±0.9mmol/L)
were lower in 2007 compared to 2003 (P<0.001; n=90 each). Endothelium-dependent vasodilation
was greater in 2007 (44±15%) compared to 2003 (28±12%; n=36 each; P<0.001). Vascular superoxide
Gxidative stress derived from endothelial NO synthase (eNOS) was lower in 2007 than in 2003 (reduction by N -nitro-
l-arginine-methyl ester, 0.29±0.21nmol/(mgmin) vs 0.09±0.20nmol/(mgmin); P=0.002). In linear
regression analysis, LDL-cholesterol levels have been shown to be the major determinant of endothelial
function in the combined 2003 and 2007 cohort.
Conclusion: Intensive lipid-lowering is associatedwith improved endothelial function and reduced super-
oxide production from eNOS. Further improvement in vascular function could be achieved by targeting
de inother sources of superoxi
. Introduction
Increased LDL-cholesterol is an important risk factor for car-
iovascular disease. We have recently shown that the levels
f LDL-cholesterol determine endothelial function and oxidative
tress inpatientswith severe coronary arterydisease [1]. Aplethora
f clinical studieshavedemonstrated that statins improveendothe-
ial function and reduce oxidative stress in patients at different
tages of cardiovascular disease [2,3]. Statins and reduction of LDL-
holesterol levels have been found to improve outcome of patients
ith cardiovascular disease [4,5]. In light of these observations,
uidelines for secondary prevention of cardiovascular disease have
een updated. In particular, there is now a focus on lower opti-
∗ Corresponding author. Tel.: +44 141 330 5420; fax: +44 141 330 6997.
E-mail addresses: c.delles@clinmed.gla.ac.uk (C. Delles), ad7e@clinmed.gla.ac.uk
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Open access under CC BY-NC-ND license.cluding xanthine oxidase.
© 2010 Elsevier Ireland Ltd. 
mum total and LDL-cholesterol targets in the US, Europe and UK
compared to previous editions of the guidelines (supplementary
Table 1). Patients known to be at cardiovascular risk may therefore
receive more intensive lipid-lowering therapy to achieve current
targets. A recent study, however, has found no additional bene-
ﬁt of aggressive lipid-lowering using simvastatin and ezetimibe
compared to simvastatin alone on reduction of carotid intima-
media thickness despite a signiﬁcance between group difference
in LDL-cholesterol [6]. The exact value of aggressive lipid-lowering
and the choice of drugs to achieve this are therefore still under
debate.
Endothelial function is an independent predictor of morbidity
and mortality in patients with cardiovascular diseases [7–9]. Being
Open access under CC BY-NC-ND license.a critical step in the cardiovascular continuum, endothelial function
may serve as a surrogate marker to monitor efﬁcacy of treatment.
From our previous cross-sectional study [1] we have suggested
that reductions in LDL-cholesterol levels will lead to improvement
of endothelial function in patients with severe CAD. We aimed to
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est this hypothesis by comparing lipid proﬁles, endothelial func-
ion and levels of vascular superoxide production in a group of
atients who underwent coronary artery bypass graft surgery in
003 with an age-matched group of patients undergoing surgery
n 2007 in whom cholesterol levels were signiﬁcantly lower in line
ith revised secondary prevention protocols.
. Methods
.1. Subjects
The present observational study derived from comparison of
wo studies which have been performed at our Centre. Data were
ollected from 105 patients with severe CAD undergoing coronary
rtery bypass surgery between November 2006 and February 2008
“2007 group”) and compared with data from a similar group of
atients studied between February 2003 and February 2004 (“2003
roup”; n=121). Patients were operated in the same clinical centre
y the same team of cardiothoracic surgeons. Blood samples were
aken from patients between one and seven days prior to surgery
fter 3h of fasting, and were stored at −70 ◦C for routine biochem-
stry including cholesterol levels. Saphenous vein segments surplus
o requirement at the time of surgery were taken to the laboratory,
leaned of excess connective tissue and stored at 4 ◦C in a HEPES
uffer for study of endothelial function and superoxide production
he following day. Within the two patient groups data on endothe-
ial functionwas available from36age-matchedpatients from2003
nd2007and from33age-matchedpatients for superoxideproduc-
ion. These subjects did not differ from the whole 2003 and 2007
roups in their clinical characteristics (supplementary Tables 2 and
).
We also recruited 106 control subjects without evidence of car-
iovascular disease. Seventy control subjects were patients who
nderwent surgery for the removal of varicose veins but were oth-
rwise healthy (n=51 in 2003 and n=19 in 2007). Saphenous vein
pecimens from non-varicosed parts of vein were processed as
bove.We age-matched the 19 patients from2007with 19 patients
rom 2003 for analysis. Total (3.7±0.7mmol/L vs 4.8±0.8mmol/L)
nd LDL-cholesterol levels (1.8±0.5mmol/L vs 2.7±1.0mmol/L)
ere available in some of these patients and in 2003 (n=14) and
007 (n=9), respectively. Patients were operated in the same hos-
ital by the same team of vascular surgeons. Thirty-six control
ubjectswere recruited in 2007 from local gymsorwere employees
f Glasgow University. They provided blood samples for assess-
ent of whole blood superoxide release and underwent in vivo
ndothelial function testing.
The study complies with the Declaration of Helsinki and was
pproved by the local ethics committee. All participants gave
nformed written consent.
.2. Endothelial function
These studies have been performed in 2003 and 2007 under the
upervision of the same experienced researcher (C.A.H.) using the
ame equipment. Three millimetre rings of saphenous vein were
tudied in organ chambers as previously described [1]. In brief,
essels were constricted with phenylephrine (3mol/L) and relax-
tion to calcium ionophore A23187 (0.01–10mol/L) was studied.
aximum relaxation was calculated and expressed as a percent-
ge of constriction to phenylephrine. In a subset of patients in
007 (n=22 patients with CAD, n=29 control subjects) we also
ssessed endothelium-dependent vasodilation in vivo. We per-
ormed pulse wave analysis using a SphygmoCor Vx device (AtCor
edical Inc, Itasca, IL, USA) and examined the maximum change
f radial augmentation index to inhaled salbutamol (400g) [10].is 211 (2010) 271–277
This was compared to maximum response to inhaled glycerol trini-
trate (400g) to assess endothelium-independent vasodilation.
Response to glycerol trinitrate was found to be similar between
patients and control subjects (−66±19% vs −70±20%, P=0.482).
2.3. Superoxide production
Basal vascular superoxide production was measured in 3–4mm
rings by chemiluminescence as described previously [1] using
lucigenin (5mol/L) by the same experienced researcher (C.A.H.)
using the same equipment in 2003 and 2007. When sufﬁcient
tissue was available the effects of the following on superox-
ide production were also studied: NG-nitro-l-arginine-methyl
ester (l-NAME) 0.1mmol/L (endothelial NO synthase inhibitor),
allopurinol 0.1mmol/L (xanthine oxidase inhibitor), dipheny-
lene iodonium (DPI) 10mol/L (NAD(P)H oxidase inhibitor) and
rotenone 3mol/L (mitochondrial superoxide inhibitor). Superox-
ide levels were calculated from a standard curve generated from
xanthine and xanthine oxidase and standardised to mg of wet
weight.
In the 2003 cohort measurements of vascular superoxide pro-
duction were conﬁrmed using dihydroethidine ﬂuorescence as
described previously [1]. In the 2007 cohort oxidative stress status
was conﬁrmed by analysing superoxide release from whole blood.
In brief, venous blood was collected in lithium heparinate contain-
ing tubes, kept on ice andprocessedwithinhalf anhour. Superoxide
levels were detected by electron paramagnetic resonance (e-scan
R; Bruker BioSpin GmbH, Rheinstetten, Germany) with the spin
probe 1-hydroxy-3-carboxy-2,2,5,5-tetramethylpyrrolidine (CPH;
Noxygen, Elzach, Germany) to a ﬁnal concentration of 500M [11].
Instrument settingswere: centreﬁeldof3375G,modulationampli-
tude of 2.27 G, sweep time of 5.24 s, sweep width of 60 G and 10
scans. Superoxide levels were recorded once a minute for 10min
and the rate of superoxide anion production was calculated as
counts per minute.
2.4. Statistical analysis
Statistical analyseswereperformedusingSPSS (version15; SPSS
Inc., Chicago, IL, USA) and Minitab (version 12.1; Minitab Inc., State
College, PA, USA) software. In text and tables, data are expressed
as mean± standard deviation or median [interquartile range] as
appropriate. In ﬁgures, means and standard errors or box plots are
givenas indicated.Normaldistributionofdatawasexaminedby the
Kolmogorov-Smirnov test and by visual inspection of Q–Q plots.
Paired and unpaired Student’s t-tests have been performed for
comparison of normally distributed data as appropriate. Wilcoxon
test has been used for comparison of data that were not normally
distributed. Fisher’s exact testhasbeenused for comparisonof cate-
gorical data. Pearson’s correlation coefﬁcients have been calculated
where indicated. Linear regression analysis was used to examine
the independent effects risk factors on endothelial function in the
whole study cohort. A P-value of less than 0.05 (two-sided) was
considered signiﬁcant.
3. Results
3.1. Clinical characteristics and cholesterol levels
Compared to the 2003 group, the 2007 group was older, had a
slightly lower diastolic blood pressure and contained more male
patients. Other clinical characteristics were not different between
the two groups (Table 1). Control subjects undergoing varicose vein
surgery were similar between 2003 (n=19; age 48±13 years) and
2007 (n=19; age 48±13 years).
C. Delles et al. / Atheroscleros
Table 1
Clinical characteristics of patients with coronary artery disease.
2003 n=121 2007 n=105 P-value
Age (years) 62 ± 9 65 ± 10 0.028
Male/female 77/44 (64%) 84/21 (80%) 0.003
Body mass index (kg/m2) 28.7±4.9 29.5±5.0 0.243
Systolic blood pressure (mmHg) 140±14 140±24 0.999
Diastolic blood pressure (mmHg) 82±11 78±12 0.009
Diabetes (yes/no) 27/94 (22%) 28/77 (27%) 0.092
Active smoking (yes/no) 28/93 (23%) 18/87 (17%) 0.071
Aspirin (yes/no) 103/18 (85%) 88/17 (84%) 0.140
Beta blocker (yes/no) 75/46 (62%) 67/38 (64%) 0.106
ACEI or ARB (yes/no) 58/63 (48%) 55/50 (52%) 0.085
Statin (yes/no) 107/14 (88%) 99/5 (94%) 0.038
Simvastatin (%) 68 58 0.148
Atorvastatin (%) 19 30 0.073
Pravastatin (%) 11 4 0.069
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Fluvastatin (%) 0 1 n/a
CEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
In patients with CAD, statin use increased from 88% in 2003
o 94% in 2007 (P=0.038). Average statin dose increased from
6±16mg/d in 2003 to 37±17mg/d in 2007 (P<0.001). This was
ssociated with lower total (4.0±0.9mmol/L vs 4.8±1.0mmol/L;
< 0.001; n=91 each) and LDL-cholesterol levels (2.0±0.7mmol/L
s 3.0±0.9mmol/L; P<0.001; n=89 each) in 2007 compared
o 2003, in the absence of changes in HDL-cholesterol levels
1.1 [0.9;1.3]mmol/L vs 1.2 [1.0;1.4]mmol/L; P=0.124; n=90;
ig. 1).
The signiﬁcant difference in cholesterol levels measured in the
ntire patient cohorts from 2003 and 2007 were also observed in
he subgroups used for assessment of endothelial function (2003:
.9±0.9mmol/L, 2007: 4.1±1.0mmol/L; P<0.001) and superox-
de production (2003: 4.9±1.2mmol/L, 2007: 4.2±1.1mmol/L;
= 0.048).
.2. Endothelial function
Patients with CAD had impaired endothelial function compared
o control subjects both ex vivo (maximum relaxation of saphenous
eins to calcium ionophore A23187; 2003: 28±13% vs 60±11%,
< 0.001; 2007: 44±16% vs 65±15%, P<0.001; Fig. 2a and b) andn vivo (maximum change in radial augmentation index to salbuta-
ol; −3.1 [−7.0;6.1]% vs −6.8 [−10.5,−3.2]%, P=0.021; Fig. 2c).
In patients with CAD, endothelial function, measured as the
aximum relaxation of saphenous veins to calcium ionophore
23187, was signiﬁcantly greater in the 2007 compared to the
ig. 1. Lipids: total (a), LDL (b) and HDL-cholesterol levels (c) in patients with coronar
nterquartile range and extremes, respectively. Numbers of experiments/samples are giveis 211 (2010) 271–277 273
2003 group (44±15% vs 28±12%, P<0.001, n=36 each; Fig. 2d).
The previously observed correlation between LDL-cholesterol and
endothelial function in the 2003 group (r=−0.275, P=0.012;n=83)
extended to the combined 2003 and 2007 cohorts (r=−0.482,
P<0.001; Fig. 2e). We performed linear regression analysis with
the vasodilatory response to A23187 as dependent variable and
entered characteristics that were different between the 2003 and
2007 cohorts with P-values less than 0.10 (age, sex, diabetes status,
smoking status, LDL-cholesterol levels, diastolic blood pressure,
statin dose, and ACEI/ARB usage) together with a variable indi-
cating the year of study (2003 or 2007; to adjust for factors not
represented by the above variables) into the model (Table 2). This
demonstrated that out of the above variables only LDL-cholesterol
contributed signiﬁcantly to endothelial function explaining 15.6%
of its variability. The relationship between LDL-cholesterol and
endothelium-dependent vasorelaxation held true if the analysis
was restricted to male patients (supplementary Figure 1).
Endothelium-dependent vasorelaxation remained unchanged
in saphenous vein from control subjects (maximum response to
calcium ionophore A23187 in 2003: 60±11%, in 2007: 65±15%;
P=0.252; n=14).
3.3. Vascular superoxide generation
Patients with CAD had greater vascular superoxide pro-
duction compared to control subjects (lucigenin enhanced
chemiluminescence; 2003: 0.78 [0.39;0.92] nmol/(mgmin)
vs 0.46 [0.28;0.67] nmol/(mgmin), P=0.003; 2007: 0.65
[0.39;0.92] nmol/(mgmin) vs 0.38 [0.25;0.64] nmol/(mgmin),
P=0.011). These results were conﬁrmed by hydroethidine ﬂuo-
rescence in the 2003 cohort (Fig. 3a) and by assessment of whole
blood superoxide release in the 2007 cohort (patients with CAD:
37.8 [32.1;75.3] kAU; control subjects: 23.8 [21.3;30.4] kAU;
P<0.001; Fig. 3b).
Levels of total vascular superoxide were not signiﬁcantly differ-
ent between the 2003 and 2007 groups of patients with CAD (0.77
[0.53;1.08] nmol/(mgmin) vs 0.50 [0.37;0.85] nmol/(mgmin);
P=0.053; n=33 each) (Fig. 3c). When the sources of super-
oxide were investigated, signiﬁcant differences between the
groups were found (Fig. 3d). A decrease in the amount of
superoxide derived from uncoupled eNOS was observed from
2003 (n=27) to 2007 (n=21) (decrease in vascular super-
oxide production by l-NAME:−0.29±0.21nmol/(mgmin) vs
−0.09±0.20nmol/(mgmin); P=0.002). Change of superoxide
production by DPI (which will inhibit production from eNOS
as well as NAD(P)H oxidase and mitochondrial sources) was
y artery disease in 2003 and 2007. Lines, boxes and whiskers represent median,
n in the boxes.
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Fig. 2. Endothelial function: (a and b) endothelial function as assessed by maximum vasodilation of saphenous vein rings to calcium ionophore A23187 (10mol/L) in
patients with coronary artery disease (CAD) and control subjects in 2003 (a) and 2007 (b). (c) Endothelial function as assessed by maximum change in radial augmentation
index (AIx) to salbutamol (400g) in patients with CAD and control subjects. (d) Endothelial function as assessed by maximum vasodilation of saphenous vein rings to
calcium ionophore A23187 (10mol/L) in age-matched patients with CAD from 2003 and 2007. (e) Scatterplot of maximum vasodilation of saphenous vein rings to calcium
ionophore A23187 (10mol/L) vs LDL-cholesterol levels in 2003 (red diamonds) and 2007 (blue squares). There is signiﬁcant correlation (r=−0.482; P<0.001) between
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rDL-cholesterol and endothelial function in the combined 2003 and 2007 cohorts
nd extremes, respectively. Numbers of experiments/samples are given in the boxe
o the web version of the article.)
umerically different between 2003 (−0.43±0.29nmol/(mgmin),
= 26) and 2007 (−0.26±0.27nmol/(mgmin), n=13) but did
ot reach statistical signiﬁcance (P=0.054). No difference in
uperoxide derived from xanthine oxidase was seen between
he 2003 (n=27) and 2007 (n=31) cohorts (decrease by allopuri-
ol, −0.12±0.18nmol/(mgmin) vs −0.08±0.22nmol/(mgmin);
= 0.341). Mitochondrial superoxide, examined for the ﬁrst
ime in the 2007 study, was also identiﬁed as a signiﬁcant
ource of superoxide in patients with CAD. Incubation with
able 2
eterminants of endothelial function in the combined 2003 and 2007 cohort.
Full model (R2 = 0.275)
ˇ
Age 0.062
Sex (0 = female; 1 =male) 0.005
Diabetes (0 =no, 1 = yes) −0.061
Active smoking (0 =no, 1 = yes) 0.128
Diastolic blood pressure −0.163
LDL-cholesterol −0.0286
ACEI/ARB (0=no, 1 = yes) −0.025
Statin dose −0.058
Year of study 0.343
n the full model all variables were forced into the model. The stepwise model was deve
espectively. ˇ indicates the partial correlation coefﬁcients. ACEI, angiotensin-convertingregression line). Lines, boxes and whiskers represent median, interquartile range
interpretation of the references to color in this ﬁgure legend, the reader is referred
rotenone reduced superoxide from 0.51 [0.39;1.00] to 0.46
[0.32;0.76] nmol/(mgmin) (P<0.001; n=47). In control subjects
the amount of superoxide generated from mitochondria was found
to be negligible (0.50±0.34 and 0.49±0.32nmol/(mgmin) in the
absence and presence of rotenone, respectively; P=0.618; n=10;
Fig. 3e).
Vascular superoxide production remained unchanged in con-
trol subjects between 2003 and 2007 (0.47±0.26nmol/(mgmin)
vs 0.43±0.32nmol/(mgmin), P=0.697; n=14).
Stepwise model (R2 = 0.156)
P-value ˇ P-value
0.558 – –
0.965 – –
0.562 – –
0.245 – –
0.140 – –
0.022 −0.395 <0.001
0.856 – –
0.597 – –
0.027 – –
loped using probabilities of F to enter and remove variables of ≤0.050 and ≥0.100,
enzyme inhibitor; ARB, angiotensin receptor blocker.
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Fig. 3. Superoxide production: (a) increased vascular superoxide production in patients with coronary artery disease (CAD; top row) compared to control subjects (bottom
row) in the 2003 cohort. Representative examples of hydroethidine ﬂuorescence (red) in saphenous vein specimens are given. Background staining with 4′-6-diamidino-2-
phenylindole (DAPI; blue). “E” indicates endothelium. (b) Whole blood superoxide production in patients with CAD (solid bar) compared to control subjects (open bar) in the
2007 cohort. (c) Superoxide production from saphenous vein assessed by lucigenin-enhanced chemiluminescence in age-matched patients with CAD from 2003 and 2007.
Lines, boxes and whiskers represent median, interquartile range and extremes, respectively. Numbers of experiments/samples are given in the boxes. (d) Sources of vascular
superoxide production in patients with CAD from 2003 (red bars) and 2007 (blue bars). Bars (means and standard errors) indicate the decrease in superoxide production
f ase in
s scular
a se (CA
r the a
4
l
u
t
e
d
w
p
t
L
h
m
m
w
i
o
t
ﬁ
l
c
t
c
sollowing incubation with diphenylene iodonium (DPI; 10mol/L; NAD(P)H oxid
ynthase inhibitor) and allopurinol (0.1mmol/L; xanthine oxidase inhibitor). (e) Va
bsence and presence of rotenone (3mol/L) in patients with coronary artery disea
eferences to color in this ﬁgure legend, the reader is referred to the web version of
. Discussion
The central ﬁnding from this study is that LDL-cholesterol
evels have been reduced between 2003 and 2007 in patients
ndergoing coronary artery bypass surgery and that this reduc-
ion in LDL-cholesterol levels is accompaniedbyan improvement in
ndothelial function. LDL-cholesterol has been shown to be amajor
eterminant of endothelium-dependent vasorelaxation in patients
ith CAD in this and in our previous study [1]. Although a large
roportion of the improvement of endothelial function from 2003
o 2007 remains unexplained, the potential contribution of lower
DL-cholesterol levels require some discussion.
Improvement of endothelial function by lipid-lowering therapy
as been shown previously in clinical studies [2,3]. In particular,
ore powerful statins and higher doses of statins improve ﬂow
ediated brachial artery vasodilation [12]. However, our present
ork is to the best of our knowledge the ﬁrst study demonstrat-
ng a marked effect of more aggressive treatment with statins
n endothelial function in routine clinical care. Our data are par-
icularly important against the background of recently published
ndings from a controlled clinical trial suggesting that aggressive
ipid-lowering does not necessarily lead to better vascular out-
ome compared to standard therapy [6]. In our study we found
hat improvement of endothelial function was paralleled by lower
holesterol levels. This may have been a consequence of higher
tatin dose but also of recently more common prescription of morehibitor), NG-nitro-l-arginine-methyl ester (l-NAME; 0.1mmol/L; endothelial NO
superoxide production assessed by lucigenin-enhanced chemiluminescence in the
D, n=47) and control subjects (n=14) of the 2007 group. (For interpretation of the
rticle.)
powerful statins such as atorvastatin althoughwe cannot prove the
latter due to small numbers and the observational nature of our
study. At least for the use of statins, higher doses, more intensive
LDL-cholesterol lowering, and improved vascular outcome appear
to go hand in hand. However, LDL-cholesterol only explains about
16% of the variability of endothelial function in patients with CAD
which leaves room for other factors that have not been addressed
in the present study or for whose detection our study was not
adequately powered.
A number of mechanisms may contribute to the adverse effects
of LDL-cholesterol on endothelial function. Oxidative modiﬁcation
of LDL-cholesterol not only results in formation of oxidised LDL-
cholesterol but alsoof free radicalswhichmay interactdirectlywith
nitric oxide reducing its bioavailability. Oxidised LDL-cholesterol
causes a depletion of caveolae cholesterol, a redistribution of
eNOS away from caveolae and a diminished capacity to activate
the enzyme [13,14]. Both LDL and oxidised LDL-cholesterols may
cause decreased eNOS transcription, although a compensatory up-
regulation of eNOS has been reported in hypercholesterolemic
rabbits [15]. LDL and oxidised LDL-cholesterols also increase
superoxide production; activation of xanthine oxidase, NAD(P)H
oxidoreductase and eNOS uncoupling all having been reported to
be involved in this cholesterol-dependentproductionof superoxide
[16–18].
The attenuation of LDL-cholesterol levels in the 2007 patient
group was associated with prescription of higher doses of statins. It
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as been reported that the beneﬁcial effects of statins on endothe-
ial function extend beyond cholesterol lowering. Statins inhibit
evalonate synthesis leading not only to reduced cholesterol syn-
hesis but also decreased isoprenylation of small GTPases and
nhibition of these signalling molecules. An example of the lat-
er would be the inhibition of RhoA and consequent inhibition of
rginase activity [19] with arginase having recently been proposed
s a novel target for treatment of atherosclerosis [20]. In addition
tatins can increase eNOS expression and induce phosphoryla-
ion and activation of eNOS via the phosphotidylinositol-3-kinase
kt pathway [21]. A reduction in superoxide production via inhi-
ition of vascular NAD(P)H oxidase expression and inhibition of
GF--Smad 2/3 signalling has also been reported [22–24] as has
ecoupling of eNOS [25]. Cholesterol-independent effects of statins
n endothelial function have been shown previously in clinical
tudies [2,3]. In addition to direct and indirect effects of statins a
umber of other factors may inﬂuence endothelial function. Dias-
olic blood pressure was lower in the more recent patient group
nd numerically, a higher proportion of patients in this group were
aking angiotensin-converting enzyme inhibitors or angiotensin
eceptorblockers,whichcouldcontributeboth tobetterbloodpres-
ure control anddecreasedproductionof superoxide fromNAD(P)H
xidase and thus lead to an improvement in endothelial function
26]. However, in regression analysis these factors were not inde-
endently associated with endothelial function.
In addition to excess superoxide generation from NAD(P)H oxi-
ase and eNOS there is increasing evidence that over-production
f reactive oxygen species by the mitochondria could contribute
o development of atherosclerotic disease [27]. In this study we
ere able to detect a signiﬁcant contribution from the mito-
hondria to vascular superoxide in patients with severe CAD but
ot in control subjects. Moreover, mitochondrial SOD deﬁciency
as been associated with hypertension in mice [28]. Increasing
itochondrial anti-oxidant systems preserve endothelial func-
ion and prevent development of atherosclerosis in apoprotein
-deﬁcient mice [29]. Parts of the effects of DPI on vascular
uperoxide production in our study may indeed reﬂect the sub-
tance’s unspeciﬁc effects on mitochondrial superoxide generating
ystems. Increased production of superoxide from xanthine oxi-
ase has been demonstrated previously in humans with coronary
rtery disease [1,30] whilst treatment with allopurinol has been
eported to normalise endothelial function in diabetic subjects
31].
We should emphasise again that our analysis suggests that
educed LDL-cholesterol levels contribute to improvements of
ndothelial function between 2003 and 2007. However, the pre-
ented regression analysis is based on a combined analysis of the
003 and 2007 cohorts where the differences in cholesterol levels
eremost striking. It clearly does not exclude the presence of other
nd possibly more important determinants of endothelial func-
ion but provide an estimate of the contribution of LDL-cholesterol
owering to improved endothelial function.
We acknowledge that our data do not derive from a controlled
linical trial. Combined analysis of data collected in 2003 and 2007
as complicated by differences in data collected in these individ-
al projects. Nevertheless, this observational study demonstrates
hat effects predicted from controlled trials hold true in clinical
ractice. Another limitation of our study is that control subjects
ere younger than patients. Control subjects were mainly used in
rder to demonstrate consistency of our measures between 2003
nd 2007; in this context age does not play a role. Results con-
erning mitochondrial superoxide production should, however, be
nterpreted against the background of a 17-year age difference.
e would also like to point out that the 2007 control group is
haracterised by lack of cholesterol data in the majority of sub-
ects. Whilst this does not affect the primary message of this study
[
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which focussed on patients with CAD, it is reassuring that in the
2003 cohort total and LDL-cholesterol levelswere lower in the con-
trol group (i.e. in the group with better endothelium-dependent
vasorelaxation) [1].
In summary, we have found a signiﬁcant improvement of
endothelial function in patients with severe CAD that is paralleled
by treatment of lipids to lower targets. Being an independent pre-
dictor of morbidity and mortality, this improvement of endothelial
function may serve as surrogate evidence for improved survival
of patients with CAD as a result of new secondary prevention
guidelines. Although a signiﬁcant reduction in superoxide produc-
tion from eNOS was observed the total superoxide production was
not signiﬁcantly lower in the 2007 compared to the 2003 group
and was almost twice that observed in the control groups. Thus
additional therapeutic strategies to lower vascular superoxide pro-
duction should be considered. Our data suggest that mitochondrial
and xanthine oxidase pathways involved in generation of reactive
oxygen species may become novel drug targets for cardiovascular
prevention.
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